Fixed duration interruptions are inferior to continuous treatment in African adults starting therapy with CD4 cell counts < 200 cells/microl.
about
Antiretroviral treatment regardless of CD4 count: the universal answer to a contextual questionScale-up of HIV treatment through PEPFAR: a historic public health achievementRandomized trial of time-limited interruptions of protease inhibitor-based antiretroviral therapy (ART) vs. continuous therapy for HIV-1 infectionCost effectiveness analysis of clinically driven versus routine laboratory monitoring of antiretroviral therapy in Uganda and ZimbabweDynamic logistic regression model and population attributable fraction to investigate the association between adherence, missed visits and mortality: a study of HIV-infected adults surviving the first year of ART.Modelling imperfect adherence to HIV induction therapyRoutine versus clinically driven laboratory monitoring of HIV antiretroviral therapy in Africa (DART): a randomised non-inferiority trialTreatment interruption and variation in tablet taking behaviour result in viral failure: a case-control study from Cape Town, South Africa.Randomized controlled trials of HIV/AIDS prevention and treatment in Africa: results from the Cochrane HIV/AIDS Specialized Register.Treatment interruption in a primary care antiretroviral therapy program in South Africa: cohort analysis of trends and risk factorsA single CD4 test with 250 cells/mm3 threshold predicts viral suppression in HIV-infected adults failing first-line therapy by clinical criteriaCD8 T-Cell Responses before and after Structured Treatment Interruption in Ugandan Adults Who Initiated ART with CD4 T Cells <200 Cell/μL: The DART Trial STI SubstudyCorrelates of unstructured antiretroviral treatment interruption in a cohort of HIV-positive individuals in British Columbia.The immunological and virological consequences of planned treatment interruptions in children with HIV infection.Residual activity of two HIV antiretroviral regimens prescribed without virological monitoringCD4+ T-cell-guided structured treatment interruptions of antiretroviral therapy in HIV disease: projecting beyond clinical trials.The Medical Research Council (UK)/Uganda Virus Research Institute Uganda Research Unit on AIDS--'25 years of research through partnerships'.Social and clinical attributes of patients who restart antiretroviral therapy in central and Copperbelt provinces, Zambia: a retrospective longitudinal study.The consequences of post-election violence on antiretroviral HIV therapy in Kenya.The Impact of Different CD4 Cell-Count Monitoring and Switching Strategies on Mortality in HIV-Infected African Adults on Antiretroviral Therapy: An Application of Dynamic Marginal Structural Models.Piecewise HIV virus dynamic model with CD4(+) T cell count-guided therapy: IOutcomes of Nigeria's HIV/AIDS Treatment Program for Patients Initiated on Antiretroviral Treatment between 2004-2012.The virological durability of first-line ART among HIV-positive adult patients in resource limited settings without virological monitoring: a retrospective analysis of DART trial data.HIV treatment and care in resource-constrained environments: challenges for the next decade.Adherence to antiretroviral therapy and acceptability of planned treatment interruptions in HIV-infected children.Effects of political conflict-induced treatment interruptions on HIV drug resistanceHIV-Related Medical Admissions to a South African District Hospital Remain Frequent Despite Effective Antiretroviral Therapy Scale-Up.Biomarkers from late pregnancy to 6 weeks postpartum in HIV-infected women who continue versus discontinue antiretroviral therapy after delivery.Unstructured treatment interruption of antiretroviral therapy in clinical practice: a systematic review.High rate of HIV resuppression after viral failure on first-line antiretroviral therapy in the absence of switch to second-line therapy.Phenotypic and genotypic analyses to guide selection of reverse transcriptase inhibitors in second-line HIV therapy following extended virological failure in Uganda.Daily co-trimoxazole prophylaxis in severely immunosuppressed HIV-infected adults in Africa started on combination antiretroviral therapy: an observational analysis of the DART cohort.Socioeconomic and clinical factors explaining the risk of unstructured antiretroviral therapy interruptions among Kenyan adult patients.Missing CD4+ cell response in randomized clinical trials of maraviroc and dolutegravir.Can antiretroviral therapy be safely interrupted and, if so, when?Barriers to retention in care as perceived by persons living with HIV in rural Ethiopia: focus group results and recommended strategies.Two-Months-off, Four-Months-on Antiretroviral Regimen Increases the Risk of Resistance, Compared with Continuous Therapy: A Randomized Trial Involving West African Adults
P2860
Q26741384-FF833E56-5B04-42BA-83AF-744B8824B58CQ26864517-77C207F6-7DF1-4350-BC8C-7DD72A847E2EQ28478848-4571D565-3540-40D6-A0C7-34D86B7ADA31Q28730357-C086CE3D-0D18-477F-AEFA-EA7BB9C3019CQ30558310-8FB901AA-8DF9-4AF0-9036-22D21E589BF2Q33523201-358D7B98-DF69-4774-9DF5-2C69561C7C25Q33587553-FE6AFCB0-054C-4E86-B58A-0393A12FC552Q33999150-7508D998-D0CE-483A-8AAA-C3EAF70FF602Q34110332-13DCF905-81E4-4AC1-9D7C-BBF5CD16A14DQ34508220-0E838BF5-0235-4551-BD47-86A54CC93C36Q34600621-A3D4D462-FD94-4BA0-8976-5CB3A65FEC14Q34730855-87E03DB5-2FCF-483C-A826-E2DE2A13BCF6Q34756298-77B27C9E-6070-4A4C-B349-2FFE2A636E39Q35032305-FD82E7C5-D351-4CC9-AD37-6B22DA15B0A4Q35270968-962DE826-9219-4788-9272-3D5AAEFF320FQ35562938-3C631768-8F7E-4961-90F9-8015476ED8AFQ35929458-215599B8-17EA-4302-A1D7-5DD15287DE36Q35973422-E857C967-A7DD-4DD6-9698-AD57920DF5F5Q36023778-DBE18663-0C25-49BA-A9EC-A8AB562D1E2FQ36089346-B51E8C4D-EBF9-4554-A2C9-68EECC059855Q36101198-8AE3ABAD-1594-49B8-9DE3-BE33A9ECEF53Q36187496-B0656F0B-389A-4A05-B77D-ECCD228A8EAAQ36286733-C19DA21F-FBF6-478F-903C-E87373FDC49FQ36386806-DCCC6D63-1320-4470-8885-71D22D73B5FBQ36542643-0CD27793-5ADB-4B0A-90C1-E8DC0266AF83Q37175897-779A4CB9-CE1B-469D-AD66-38BD83B630D1Q37328357-80FD1B6E-0440-42D9-B31D-8568F9CF0815Q37404428-AA20C62D-2D1A-4A50-9490-DD3856473303Q37896165-6DCE9AAF-BF38-4C59-A037-B1DDD280D626Q38264778-D61CD845-8392-47C4-9C90-95D806B589F6Q38848190-E171DA0A-908D-4EDA-8C5B-2297E30AE34EQ38872771-457DD16B-3B02-4A1E-8D32-7C4A543A89D5Q40023160-1380A6D2-443E-42BA-9DB0-8B357A7FF6F2Q40544015-15638BF3-99B7-4706-A155-7E058BEF7E76Q43607040-3910A964-FCEB-43C6-B79F-FD35091A00D7Q43648422-A673FE7F-11B1-4AA6-A392-6E4556282B90Q58827996-29FD73EC-8D61-4990-91DE-0B59CB9E9F45
P2860
Fixed duration interruptions are inferior to continuous treatment in African adults starting therapy with CD4 cell counts < 200 cells/microl.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Fixed duration interruptions a ...... ell counts < 200 cells/microl.
@en
Fixed duration interruptions a ...... ell counts < 200 cells/microl.
@nl
type
label
Fixed duration interruptions a ...... ell counts < 200 cells/microl.
@en
Fixed duration interruptions a ...... ell counts < 200 cells/microl.
@nl
prefLabel
Fixed duration interruptions a ...... ell counts < 200 cells/microl.
@en
Fixed duration interruptions a ...... ell counts < 200 cells/microl.
@nl
P1433
P1476
Fixed duration interruptions a ...... ell counts < 200 cells/microl.
@en
P2093
DART Trial Team
P304
P356
10.1097/QAD.0B013E3282F2D760
P407
P577
2008-01-01T00:00:00Z